Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) announces the departure of Mr. Tim Laidler as a director on the Board of the Company, effective immediately. On behalf of the Board, Mr. Tim Moore, Chairman of the Board, stated, “Mr. Laidler has been instrumental in […]
HAVN LIFE ANNOUNCES DEPARTURE OF TIM LAIDLER AS DIRECTOR Read More »
Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) announces that the board of directors of the Company (the “Board”), on the advice of the Company’s Chief Financial Officer, has determined that the Company is no longer a going concern as it is unable to meet
HAVN Life Provides Corporate Update Read More »
Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce that it has closed the initial tranche (the “First Tranche“) of its financing commitment (the “Financing“) by
Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to annouce that it will complete a consolidation (“Consolidation”) of its issued and outstanding common shares on the basis
HAVN Life Announces a 30:1 Consolidation of its Common Shares Read More »
The Company is a designated supplier, providing cGMP psilocybin to Project Solace participants Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce its participation in Project
Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce that Alpha Blue Ocean (“ABO“) is supporting the Company’s growth with a CAD$9,000,000 financing arrangement whereby the
This new partnership will see the distribution of the Company’s standardized, naturally derived, psilocybin containing mushrooms for therapeutic use at Healing Escapes Foundation retreats in Jamaica Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) a biotechnology company pursuing standardized extraction of psychoactive compounds and the
HAVN Life Enters Supply Agreement with MPB Group Inc. Read More »
The Company’s segment will be aired on public television networks across the U.S. starting in July, with interviews featuring CEO Tim Moore and the team leading HAVN Life’s Research and Development Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) a biotechnology company pursuing standardized extraction
HAVN Life To Be Featured On Viewpoint with Dennis Quaid Read More »
Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) announces the departure of Messrs. Victor Neufeld and Dennis Staudt, respectively, as Directors of the Company (“Board”), effective immediately. The Company expresses its appreciation for Mr. Neufeld and Mr. Staudt’s services to the Company and wishes them
HAVN Life Announces Changes to the Board of Directors Read More »
CEO Tim Moore will share recent partnership and distribution news and a roadmap for the Company’s plans for the next quarter Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support
HAVN Life to Present at Upcoming LD Micro Invitational XI Read More »
